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Abstract
The Tibetan herbal remedy PADMA 28 revealed promising results to support treatment of
atherosclerosis, Charot syndrome (intermittent claudication), chronic active hepatitis and infection
of the respiratory tract. The remedy was confirmed to be closely linked with anti- and pro-
oxidative properties in vitro. In this study, apoptogenic and survival effects of PADMA 28 were
investigated in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2.
PADMA 28 led to a concentration-dependent inhibition of cell proliferation accompanied by the
accumulation of CEM-C7H2 cells in subG1 phase, fragmentation of poly (ADP-ribose) polymerase
(PARP) and nuclear body formation. Treatment with PADMA 28 rescued to some extent cells
over-expressing Bcl-2 from apoptosis. This finding suggests that the mechanism of action of
PADMA 28 may be via interference with Bcl-2 triggered survival pathways.
Background
In its composition, PADMA 28 largely corresponds to an
herbal formula derived from Tibetan medicine that was
used in Poland in the first half of the 20th century against
chronic inflammatory diseases. In the past two decades,
this formula has been administered with or without
boiled water cooled to lukewarm hot water to a large
number of patients suffering from peripheral vascular
occlusive disease in Europe and revealed promising
results in intermittent claudication [1], atherosclerosis
[2], and chronic active hepatitis B [3].
It was reported to have both anti- and pro-oxidative prop-
erties in vitro [4]. In mouse macrophages PADMA 28 was
found to inhibit inducible nitric oxide synthesis (iNOS)
by decreasing iNOS mRNA and iNOS protein levels [5].
Recently, Neurauter et al. demonstrated that PADMA 28
modulates interferon γ-induced tryptophan degradation
and neopterin production in human peripheral blood
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mononuclear cells (PBMC) [6]. Others have reported on
its anti-inflammatory and anti-atherogenic properties [7].
It is generally accepted that improper functioning of cellu-
lar suicide or apoptosis is one of the master switches in
tumourigenesis [8-10]. Accumulation of cells in subG1
phase, degradation of poly (ADP-ribose) polymerase
(PARP) and nuclear body formation are hallmarks of
apoptosis. In this study, using CEM-C7H2 leukaemia
cells, we investigated whether and in what way PADMA 28
influences apoptosis.
Bcl-2 is the central gene family member involved in bal-
ancing between cell death and cell survival [11]. In the
present study, the influence of PADMA 28 on Bcl-2 signal-
ling in CEM-C7H2 cells deficient in functional p53 and
p16 signalling was studied in a CEM sub-line constructed
with the Bujard system in which the Bcl-2 gene is induced
upon withdrawal of tetracycline [12].
Methods
Test substance
PADMA 28 was provided in powder form as an active sub-
stance mixture without excipients by PADMA Inc. Schw-
erzenbach, Switzerland. The herbal mixture is a fine
brown dusty powder with a characteristic pungent smell.
It is a mixture of a variety of different herbs (403 mg of
active ingredients): Aegle marmelos (Bengal Quince) fruit
(20 mg); Pimenta dioica (Allspice) fruit (25 mg); Aquilegia
vulgaris (Columbine) aerial part (15 mg); Calendula offici-
nalis  (Marigold) flower (5 mg); Elettaria cardamomum
(Cardamom) fruit (30 mg); Syzygium aromaticum (Clove)
flower bud (12 mg); Saussurea lappa (Saussuria) root (40
mg); Hedychium spicatum (Hedychium) rhizome (10 mg);
Lactuca sativa (Lettuce) leaf (6 mg); Cetraria islandica (Ice-
land moss) thallus (40 mg); Glycyrrhiza glabra (Licorice)
root (15 mg); Azadirachta indica (Margosa) fruit (35 mg);
Terminalia chebula (Myrobalan) fruit (30 mg); Plantago
lanceolata (Ribwort) aerial part (15 mg); Polygonum avicu-
lare  (Knot-grass) aerial part (15 mg); Potentilla aurea
(Golden Cinquefoil) aerial part (15 mg); Pterocarpus san-
talinus (Red Sandalwood) wood (30 mg); Sida cordifolia
(Heart-leaved Sida) aerial part (10 mg); Valeriana officina-
lis (Valerian) root (10 mg); and Aconitum napellus (Monk-
shood) tuber (1 mg). Also present are 2 non-herbal
components: Dextrocamphora (natural camphor) (4 mg)
and Calcii sulphas pulv.(Gipsum; 20 mg).
In parallel, a derivative of this mixture, PADMA Basic, was
also studied and its effects compared to PADMA 28. In
view of different pharmaceutical standards in Austria and
United States, Aconitum napellus is omitted in PADMA
Basic.
Since the data on PADMA 28 were fully concordant with
those on PADMA Basic only figures showing PADMA 28
data are shown.
Individual constituents as well as the whole mixtures were
inspected and manufactured according to good manufac-
turing practice (GMP). The presence of heavy metals, pes-
ticides and organic phosphate was controlled by high
pressure liquid chromatography (HPLC). Thin layer chro-
matography, using a TLC-scanner, was used to fingerprint
each batch of every individual component (e.g. essential
oils). Terpenes were monitored by gas chromatography
and mass spectrometry. Batches were rejected when
results of fingerprinting differed substantially from that of
reference material.
Cell lines, culture conditions and transient transfection 
procedures
CEM-C7H2, a glucocorticoid-sensitive sub-line of CCRF-
CEM-C7 cells [13], was cultured in RPMI 1640 medium
(PAA Laboratories, Linz, Austria) supplemented with 10%
heat-inactivated fetal calf serum (Biochrom, Berlin, Ger-
many), 100 U/ml penicillin, 100 µg/ml streptomycin
(Bio-Whittaker, Walkersville, MD), and 2 mM L-
glutamine (Serva, Heidelberg, Germany) at 37°C in a
humidified environment of 95% air and 5% CO2. African
green monkey kidney fibroblasts (COS-1, 106/100-mm
dish) cells were kept at logarithmic growth phase in Dul-
becco's Modified Eagle Medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum, and 2 mM L-
glutamine in a humidified atmosphere containing 5%
CO2.
Two h post-transfection, cells were washed with pre-
warmed DMEM and kept in RPMI. 24 h before harvesting
the cells PADMA 28 extracts or solvent controls were
added.
Stock solutions of PADMA 28 and PADMA Basic were pre-
pared in ethanol (EtOH 70%, v/v), methanol (MeOH),
and dimethylsulfoxide (DMSO, 1:1 distilled water) and
kept at -20°C. Powdered PADMA 28 (400 mg) was vigor-
ously mixed in a total volume of 2 ml of solvent and
shaken for 30 min at 180 rpm at 37°C. The mixture was
centrifuged at 2,000 × g for 10 min and the supernatants
were sterile-filtered (pore size 0.22 µm). Cells were treated
with various concentrations of PADMA 28 or PADMA
Basic (final concentration range 0.4 mg/ml (1:500) – 1.0
mg/ml (1:200) solvent).
In parallel experiments, effects of pure ethanol, methanol
and DMSO (Merck, Darmstadt, Germany) in concentra-
tions comparable to the highest concentration in diluted
PADMA 28 extracts were investigated. Viability of cellsJournal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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after application was determined by the trypan blue exclu-
sion method.
Fluorescence Imaging
48 h after transfection, cover slips were washed twice with
PBS (140 mM NaCl, 2.7 mM KCl, 4.6 mM Na2HPO4 × 12
H2O, 1.3 mM NaH2PO4 × H2O), and cells were fixed with
a 4% solution of p-formaldehyde for 15 min and if neces-
sary, the nuclei were stained by addition of 1 µg/ml DAPI
(4',6'-diamidine-2'-phenylindole dihydrochloride, Roche
Molecular Biochemicals) diluted in PBS for 10 min.
Finally, the cover slips were washed three times with PBS
and mounted on slides with Mowiol mounting solution
(Calbiochem, Switzerland). Microscopy studies were per-
formed by employing an Olympus BX50 fluorescence
microscope and images were taken with the digital camera
Microview TE/CCD1317-K/1 (Princeton Scientific Instru-
ments, USA). Imaging analysis was performed by using
the  Metamorph imaging software (Universal Imaging
Corporation).
Flow Cytometry
Detection of apoptotic cells was by FACS analysis of
nuclear propidium iodide stained CEM cells. Briefly, 5 ×
105 cells were permeabilized and stained with 750 µl pro-
pidium iodide (50 µg/ml in 0.1% Triton X-100/0.1%
sodium citrate) and subjected to apoptosis analysis in a
FACScan (FL-2 channel, Becton Dickinson, San Jose, CA,
USA; equipped with an argon laser). Based on propidium
iodide staining, cells in the sub-G1 marker window were
considered to be apoptotic. Along with nuclear propid-
ium iodide fluorescence, light scattering was also meas-
ured. According to the light scattering analysis, apoptotic
nuclei are recognized as being smaller (lower forward
scatter values) and more granulated (higher sideward scat-
ter values). Cell debris and small particles were excluded
from the analysis by forward/sideward scatter criteria as
described elsewhere [14].
PARP cleavage
CEM-C7H2 cells were seeded in 100-mm diameter dishes.
Logarithmically growing cells were washed once with ice-
cold phosphate-buffered saline (PBS) and lysed in 0.5 ml
of Triton X-100 lysis buffer (50 mM Tris/HCl, pH 7.3, 50
mM NaCl, 5 mM Na2HPO4 × 12 H2O, 5 mM NaF, 5 mM
EDTA, 50 µg/ml of both aprotinin and leupeptin, and 2%
Triton X-100) for 20 min on ice. Lysates were clarified by
centrifugation at 10.000 × g for 10 min at 4°C after a sub-
sequent sonification procedure. Protein concentrations
were determined according to Bradford. After boiling the
samples for 5 min, equal amounts of proteins were sepa-
rated on a 10% SDS-polyacrylamide gel electrophoresis.
Transfer to Immobilon-P PVDF membranes (Millipore,
Vienna) was in 25 mM Tris/HCl, pH 7.5, 193 mM glycine,
20% (v/v) methanol, and 0.1% SDS at 300 mA constant
for 1 h. After blotting, membranes were soaked for 10 min
in methanol and washed three times in TBST (50 mM
Tris/HCl, pH 7.5, 150 mM NaCl, and 0.5% (v/v) Tween
20). Membranes were blocked overnight with TBST con-
taining 5% (w/v) skimmed milk powder at 4°C and then
probed with mouse anti-PARP antibody (diluted at 1:200
in blocking solution, Calbiochem, catalogue number 30-
100UG) for 1 h at room temperature. After washing in
TBST (4 times for 15 min) the blots were incubated with
horseradish peroxidase-conjugated anti-mouse IgG
(1:2000 dilution in blocking solution) for 45 min at room
temperature. Membranes were washed again in TBST (4
times, 15 min) and immuno-reactive bands were visual-
ized by enhanced chemiluminiscence detection (ECL,
Amersham, Vienna, Austria).
Results
Proliferation, inhibition and morphological alterations of
CEM-C7H2 cells induced by PADMA 28. CEM-C7H2 cells
were treated with various concentrations of PADMA 28.
Proliferation was determined by counting cell numbers in
a Coulter counter. Figure 1 shows that application of var-
ious concentrations of PADMA 28 (0.4 mg/ml; 1.0 mg/
ml) inhibited CEM cell proliferation in a concentration-
and time-dependent manner. Adding PBS solved extracts
at the same concentrations were less effective than alco-
holic extracts, suggesting that pharmacologically active
ingredients of PADMA 28 are extracted better by unpolar
solvents. DMSO alone at the concentrations applied did
not have any effect on cell proliferation.
In cultivated CEM cells treated with PADMA 28, morpho-
logical alterations of the nuclei characteristic for apoptosis
were visible. This is shown in panel D of Figure 2.
PADMA 28-induced subG1 transition
The G1 phase and the G1/S transition state of the cell cycle
are critical points at which the cell assesses whether it
should enter another full round of division, stop growing,
or die.
Transition of cell populations from G1/Go to subG1
phase is a frequent sign of apoptosis. As shown in Figure
3, application of 1 mg/ml PADMA 28 for 48 h resulted in
accumulation of approximately 50% of cells in subG1
phase.
PARP cleavage kinetic
Activation of pre-existing pro-caspases takes place in a
hierarchically ordered sequence starting with activation of
initiator caspases and leading to activation of effector cas-
pases such as caspase 3. Caspases 3 cleaves a number of
proteins, a prominent substrate being poly (ADP-ribose)
polymerase (PARP) [15]. PARP is a zinc-finger DNA-bind-
ing enzyme that detects DNA strand breaks generated byJournal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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genotoxic agents such as oxygen radicals. PARP is acti-
vated at an intermediate stage of apoptosis and is inacti-
vated by proteolytic cleavage at a late stage by casapase 3
and caspase 7. We raised the question whether treatment
of CEM cells with PADMA 28 causes a caspase 3- or 7-
mediated proteolytic cleavage of PARP. Figure 4 shows
this was indeed the case. Treatment of CEM-C7H2 cells
for 34 h caused a distinct proteolytic fragmentation of
PARP, with accumulation of the 89 kDa fragment (lower
bands) and concomitant disappearance of the full-size
113 kDa (upper bands) fraction (Figure 4, slot 4, 6, and
8). As was the case with growth inhibitory effect, PBS solu-
tions of PADMA 28 were less effective than ethanolic,
methanolic or DMSO extracts.
PADMA 28 interferes with Bcl-2 function
Whether a cell lives or dies is largely determined by the
Bcl-2 function [11]. If PADMA 28 triggers apoptosis by
interfering with pro-survival Bcl-2 signalling, it should be
possible to diminish the pro-apoptotic signal by overex-
pression of Bcl-2. As shown in Figures 5/6, PADMA 28-
mediated induction of apoptosis was diminished (Figure
5, bar 6 and 8) by transient overexpression of Bcl-2 in a
CEM cell sub-line in which expression of the
Influence of PADMA 28 on cell proliferation in CEM-C7H2 cells Figure 1
Influence of PADMA 28 on cell proliferation in CEM-C7H2 cells. After a growth period of 24 h, CEM-C7H2 cells were treated 
with different concentrations of PADMA 28 (0.4 mg/ml (1:500) and 1 mg/ml (1:200). After various application periods, cells 
were harvested, washed with ice-cold PBS and counted in a Coulter counter to determine cell proliferation rates. Cell dimen-
sion gates were set at 8,55 and 29,95 µm. Representative cell numbers are shown. No unspecific effects of the solvent controls 
were detectable during the incubation period in the cell culture. Data are expressed as cell numbers of untreated controls (± 
SEM, p < 0.01) of at least three independent experiments done in triplicate. For comparison of grouped data Student's t-test 
was applied. P-values below 0.05 were considered to indicate significant differences.Journal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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corresponding trans-gene was induced by withdrawal of
doxocycline (Bujard system, CEM C7H2 Bcl-2 TET off).
Bcl-2 expression is controlled, to some extent, by libera-
tion of the Th1-type cytokine IFN-γ [16]. Hence we would
like to suggest that PADMA 28 may modulate apop-
togenic pathways controlled by interferon-γ.
In this context it should be mentioned that PADMA 28
has been reported to modulate interferon-γ-induced tryp-
tophan degradation and neopterin production in human
peripheral blood mononuclear cells (PBMC) from
healthy donors [6].
Discussion
Here we show that PADMA 28 added to T cell-derived
lymphatic leukaemia cells in culture has a pronounced
concentration- and time-dependent anti-proliferative
effect. The inhibition of cell proliferation is accompanied
by nuclear body formation a morphological signs of
apoptosis. Furthermore hallmarks of apoptosis, such as
the accumulation of cells in subG1 phase, and fragmenta-
tion of poly (ADP-ribose) polymerase (PARP) could be
detected.
A growing body of evidence demonstrates that cell sur-
vival and cell death are largely determined by the function
of Bcl-2 family members. Here we show that induction of
apoptosis by PADMA 28 can be effectively counteracted
Morphological alterations of CEM-C7H2 cells after treatment with PADMA 28 Figure 2
Morphological alterations of CEM-C7H2 cells after treatment with PADMA 28. CEM-C7H2 cells were either treated with sol-
vent (DMSO) or 0.4 mg/ml of PADMA 28 for 48 h. Cells were stained with DAPI (right panels C/D; 100x) or left unstained 
(left panels A/B; 10x). Nuclear body formation was examined by fluorescence microscopy. Morphological alterations were ana-
lysed by employing transmitted light microscopy (Zeiss) of cells growing on glass cover slips.Journal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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by overexpression of the pro-survival protein Bcl-2. Based
on our data we suggest that PADMA 28 may act in a pro-
apoptotic fashion by interfering with Bcl-2 signalling.
Bcl-2 expression is, partially, controlled by interferon-γ
[16,17]. An influence of PADMA 28 on interferon-γ-medi-
ated signals was recently demonstrated by Neurauter et al.
[6] in peripheral blood mononuclear cells (PBMCs). They
found that PADMA 28 has a pronounced effect on inter-
feron-γ-stimulated neopterin production and tryptophan
degradation in stimulated PBMC [6]. This observation
appears to be of particular importance since cytokine-
induced tryptophan degradation by indoleamine (2,3)-
dioxygenase (IDO) is a potent mechanism to induce
apoptosis and T-cell tolerance via deprivation of the
essential amino acid tryptophan and by the pro-apoptotic
activity of several tryptophan catabolites formed upon
this enzyme reaction [18]. Moreover, evidence is accumu-
lating that activation of IDO may represent an immune
escape mechanism of tumour cells [19].
Assuming that stimulation of PBMC by mitogens elicits
oxidative stress in culture, it seems reasonable to suggest
that the above-mentioned effect of PADMA 28 is due to its
ability to function as an antioxidant. This assumption is in
agreement with findings that PADMA 28 decreases iNOS
mRNA levels of mouse macrophages [5], a fundamental
process that might contribute to the anti-inflammatory
activities demonstrated by others [2-7].
PADMA 28-induced subG1 transition Figure 3
PADMA 28-induced subG1 transition. SubG1 transition was 
detected by employing FACS analysis as described under 
Methods. Representative subG1 populations calculated from 
FACS histograms are shown. Data are expressed as the per-
centage of subG1 cells calculated as the means (± SEM., n = 
9, p < 0.01) of three independent experiments done in tripli-
cate. As indicated, identical results were obtained with 
another solvent.
Kinetics of PARP cleavage Figure 4
Kinetics of PARP cleavage. CEM-C7H2 cells were cultivated 
as described under Methods. Following treatment of cells 
with 0.1 mg/ml PADMA 28 for 24 h, PARP cleavage was 
detected by Western blotting. A representative cleavage pat-
tern out of three independent experiments is shown. Upper 
bands show uncleaved PARP (113 kDa), lower bands corre-
spond to a PARP cleavage product of 89 kDa. As shown for 
the growth inhibitory effect, PBS solutions were less effective 
than ethanolic or methanolic ones.
PADMA 28 interferes with Bcl-2 function Figure 5
PADMA 28 interferes with Bcl-2 function. CEM-C7H2 as 
well as CEM-C7H2Bcl2-TET-off cells were cultivated in the 
presence (Bcl2 repressed) or absence (Bcl2 expressed) of 
200 µg/ml tetracycline; 24 h after seeding, cells were treated 
with a solution of 0.4 mg/ml PADMA 28 (1:200 EtOH). After 
24 and 48 h, cells were harvested and analysed by FACS as 
described under Methods. Data are expressed as percent of 
untreated solvent controls (± SEM, ± SEM, p < 0.03) of at 
least three independent experiments done in triplicate.Journal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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Although PADMA 28 has been demonstrated to inhibit
cell proliferation and cause apoptosis under cell culture
conditions, one major question is left unanswered: is
there any therapeutic window for using a multifactorial
herbal remedy, such as PADMA 28, as a supplement in the
treatment of leukaemia patients?
Chemotherapeutic agents are most effective when admin-
istered in combination (e.g. CHOP, chemotherapeutic
multifactorial regimen comprising of doxorubicin, cyclo-
phosphamide, vincristin and prednisone). Traditional
Chinese or Tibetan medicine uses mixtures of naturally
occurring herbs and herbal extracts for cancer therapy.
Many of the commonly used herbal remedies that have
Corresponding FACS blots of figure 5 Figure 6
Corresponding FACS blots of figure 5.Journal of Carcinogenesis 2005, 4:15 http://www.carcinogenesis.com/content/4/1/15
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been tested have yielded activities that disappeared when
the extracts were fractionated into individual chemical
components. We agree with Curtis T. Keith et al. (Nature
Reviews, Drug Discovery, 2005) [20] that a focus on mul-
ticomponent therapeutics might lead to new insights in
drug discovery and that multifactorial therapeutics are
necessary for the treatment of multifactorial diseases. In
agreement with this concept, PADMA 28, a multifactorial
herbal formula, might be similarly effective as a chemo-
therapeutic agent administered as a supplement, and/or
be able to minimize the toxic side effects of such a
regimen.
It is not clear to what extent one can extrapolate results
from our cell culture experiments to possible effects in
humans. Not all of the compounds can be efficiently
absorbed, and a gradient exists between the concentra-
tions present in the extracts and the ones established in
the blood. Nevertheless, one can assume the presence of
all ingredients in the gastrointestinal tract at reasonable
concentrations, which makes anti-inflammatory and pro-
apoptotic potency more likely. This assumption is further
reinforced by the fact that PADMA 28 is successfully used
to treat intermittent claudication, atherosclerosis, sclero-
derma, multiple sclerosis, and chronic hepatitis.
Clinical trials are required for determining whether
PADMA 28 can be effectively used in the treatment of can-
cers. However, biochemical studies might help bridge the
gap between conventional and alternative tumor therapy
strategies. Additional studies focusing on the biological
significance of PADMA 28-enhanced apoptosis in various
cell systems will greatly extend our understanding of the
mode of action of this remedy. In order to clarify the bio-
logical function of PADMA 28 in molecular fashion, gene
expression profiling experiments by employing Affyme-
trix technology are currently under way.
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